Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Anal Toxicol ; 40(3): 229-35, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26861671

ABSTRACT

Biomedical samples may be used to determine human exposure to nerve agents through the analysis of specific biomarkers. Samples received may include serum, plasma, whole blood, lysed blood and, due to the toxicity of these compounds, postmortem blood. To quantitate metabolites resulting from exposure to sarin (GB), soman (GD), cyclosarin (GF), VX and VR, these blood matrices were evaluated individually for precision, accuracy, sensitivity and specificity. Accuracies for these metabolites ranged from 100 to 113% with coefficients of variation ranging from 2.31 to 13.5% across a reportable range of 1-100 ng/mL meeting FDA recommended guidelines for bioanalytical methods in all five matrices. Limits of detection were calculated to be 0.09-0.043 ng/mL, and no interferences were detected in unexposed matrix samples. The use of serum calibrators was also determined to be a suitable alternative to matrix-matched calibrators. Finally, to provide a comparative value between whole blood and plasma, the ratio of the five nerve agent metabolites measured in whole blood versus plasma was determined. Analysis of individual whole blood samples (n = 40), fortified with nerve agent metabolites across the reportable range, resulted in average nerve agent metabolite blood to plasma ratios ranging from 0.53 to 0.56. This study demonstrates the accurate and precise quantitation of nerve agent metabolites in serum, plasma, whole blood, lysed blood and postmortem blood. It also provides a comparative value between whole blood and plasma samples, which can assist epidemiologists and physicians with interpretation of test results from blood specimens obtained under variable conditions.


Subject(s)
Nerve Agents/analysis , Drug Stability , Humans , Limit of Detection , Nerve Agents/chemistry , Nerve Agents/metabolism
2.
Open Med ; 8(4): e105-15, 2014.
Article in English | MEDLINE | ID: mdl-25426178

ABSTRACT

Dengue fever, also known as breakbone fever, is a mosquito-borne infectious tropical disease caused by the dengue virus. Symptoms include fever, headache, muscle and joint pains, and a characteristic skin rash that is similar to measles. In a small proportion of cases, the disease develops into life-threatening dengue hemorrhagic fever, which results in bleeding, thrombocytopenia, and leakage of blood plasma, or into dengue shock syndrome, in which dangerously low blood pressure occurs. Treatment of acute dengue fever is supportive, with either oral or intravenous rehydration for mild or moderate disease and use of intravenous fluids and blood transfusion for more severe cases. Along with attempts to eliminate the mosquito vector, work is ongoing to develop a vaccine and medications targeted directly at the virus.


Subject(s)
Dengue/physiopathology , Animals , Dengue/prevention & control , Dengue/therapy , Dengue Vaccines , Fluid Therapy , Humans , Insect Vectors , Mosquito Control
3.
Chemosphere ; 91(2): 115-7, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23232044

ABSTRACT

We assessed the potential impact of temperature on the long-term stability of several polyfluoroalkyl chemicals in serum. We evaluated the concentrations of perfluorooctane sulfonate, perfluorohexane sulfonate, perfluorooctanoate and perfluorononanoate in 16 human serum samples stored at room temperature, 5 °C, -20 °C and -70 °C at several time points during an eight month period. Concentrations of the target analytes remained unchanged under all studied conditions, even when serum was kept at room temperature for 10 days.


Subject(s)
Drug Storage/methods , Fluorocarbons/chemistry , Serum/chemistry , Temperature , Drug Stability , Environmental Monitoring/methods , Humans
4.
J Chromatogr A ; 1218(15): 2133-7, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21084089

ABSTRACT

Perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid, two of the most widely studied polyfluoroalkyl chemicals (PFCs), can cross the placenta. Therefore, data on the exposure to PFCs of the very young are needed to evaluate the potential health effects associated with such exposure. Human serum, especially serum collected from pregnant women and cord serum, may contain endogenous components that can interfere in the separation by high performance liquid chromatography (HPLC) of PFOS and another PFC of interest, perfluorohexane sulfonic acid (PFHxS), from other serum biomolecules. The presence of such interferences may prevent the adequate quantification of PFOS and PFHxS in cord serum or serum collected from pregnant women, and potentially hinder the assessment of gestational exposure to these important PFCs using biomonitoring. We have modified our on-line solid phase extraction-HPLC-isotope dilution-tandem mass spectrometry analytical method for measuring PFCs in serum and developed an approach that allows for the elimination of these potential interferences without compromising analytical sensitivity and throughput. The combination of acetonitrile as the HPLC mobile phase organic solvent and a Betasil C8 HPLC column provided the best separation of PFOS and PFHxS from interferent peaks. In addition to eliminating these interferences, the acetonitrile method has a shorter runtime and is more sensitive for most PFCs (limits of detection were 0.1 ng/mL except for PFOS (0.2 ng/mL)) than our previous method that used methanol for the HPLC separation. The present method should improve the precise and selective analysis of maternal and cord serum for PFCs.


Subject(s)
Alkanesulfonic Acids/blood , Caprylates/blood , Chromatography, High Pressure Liquid/methods , Fetal Blood/chemistry , Fluorocarbons/blood , Pregnancy/blood , Sulfonic Acids/blood , Acetonitriles , Animals , Cattle , Female , Humans , Reproducibility of Results , Sensitivity and Specificity , Solid Phase Extraction
5.
Reprod Toxicol ; 27(3-4): 289-298, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19095057

ABSTRACT

The adverse consequences of developmental exposures to perfluorooctanoic acid (PFOA) are established in mice, and include impaired development of the mammary gland (MG). However, the relationships between timing or route of exposure, and consequences in the MG have not been characterized. To address the effects of these variables on the onset and persistence of MG effects in female offspring, timed pregnant CD-1 dams received PFOA by oral gavage over various gestational durations. Cross-fostering studies identified the 5mg/kg dose, under either lactational- or intrauterine-only exposures, to delay MG development as early as postnatal day (PND) 1, persisting beyond PND 63. Intrauterine exposure during the final days of pregnancy caused adverse MG developmental effects similar to that of extended gestational exposures. These studies confirm a window of MG sensitivity in late fetal and early neonatal life, and demonstrate developmental PFOA exposure results in early and persistent MG effects, suggesting permanent consequences.


Subject(s)
Caprylates/toxicity , Environmental Pollutants/toxicity , Fluorocarbons/toxicity , Mammary Glands, Animal/drug effects , Animals , Caprylates/administration & dosage , Environmental Pollutants/administration & dosage , Female , Fetal Development/drug effects , Fluorocarbons/administration & dosage , Gestational Age , Mammary Glands, Animal/growth & development , Maternal Deprivation , Maternal Exposure , Mice , Mice, Inbred Strains , Pregnancy , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...